NASDAQ:VCYTVeracyte Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veracyte Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $31.38 -0.83 (-2.58 %) (As of 08/5/2020 03:23 PM ET) Add Compare Share Today's Range$29.60Now: $31.38▼$32.1450-Day Range$23.06MA: $28.61▼$35.6752-Week Range$13.90Now: $31.38▼$36.42Volume325,074 shsAverage Volume539,023 shsMarket Capitalization$1.59 billionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson, LLC and Johnson & Johnson's Lung Cancer Initiative to advance diagnostics of a nasal swab test for early lung cancer detection; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and an agreement with Johnson & Johnson Services, Inc. for the development and commercialization of novel diagnostic tests to detect lung cancer. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More Beat the Market (BTM) Rank™ 2.5 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Veracyte has a potential upside of 20.2% from its current price of $31.61.Amount of Analyst CoverageVeracyte has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesVeracyte has received 372 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeracyte has received 241 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeracyte has received 60.69% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote “Outperform” if you believe VCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,853,392.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.67) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -50.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -50.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 7.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT Previous Symbol CUSIPN/A CIK1384101 Webwww.veracyte.com Phone650-243-6300Debt Debt-to-Equity RatioN/A Current Ratio13.18 Quick Ratio12.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$120.37 million Price / Sales13.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.47 per share Price / Book7.02Profitability EPS (Most Recent Fiscal Year)($0.27) Net Income$-12,600,000.00 Net Margins-27.49% Return on Equity-13.35% Return on Assets-11.68%Miscellaneous Employees270 Outstanding Shares50,580,000Market Cap$1.59 billion Next Earnings Date10/27/2020 (Estimated) OptionableOptionable $31.38 -0.83 (-2.58 %) (As of 08/5/2020 03:23 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VCYT News and Ratings via Email Sign-up to receive the latest news and ratings for VCYT and its competitors with MarketBeat's FREE daily newsletter. Veracyte (NASDAQ:VCYT) Frequently Asked Questions How has Veracyte's stock been impacted by COVID-19 (Coronavirus)? Veracyte's stock was trading at $23.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VCYT shares have increased by 33.2% and is now trading at $31.38. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Veracyte? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veracyte. When is Veracyte's next earnings date? Veracyte is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020. View our earnings forecast for Veracyte. How were Veracyte's earnings last quarter? Veracyte Inc (NASDAQ:VCYT) announced its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.22) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.22). The biotechnology company earned $20.70 million during the quarter, compared to analyst estimates of $17.56 million. Veracyte had a negative net margin of 27.49% and a negative return on equity of 13.35%. View Veracyte's earnings history. What price target have analysts set for VCYT? 3 equities research analysts have issued 12-month price objectives for Veracyte's shares. Their forecasts range from $37.00 to $40.00. On average, they expect Veracyte's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 21.1% from the stock's current price. View analysts' price targets for Veracyte. Has Veracyte been receiving favorable news coverage? Press coverage about VCYT stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Veracyte earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View the latest news about Veracyte. Are investors shorting Veracyte? Veracyte saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 6,030,000 shares, an increase of 12.1% from the June 30th total of 5,380,000 shares. Based on an average trading volume of 472,500 shares, the days-to-cover ratio is presently 12.8 days. Approximately 12.6% of the company's shares are sold short. View Veracyte's Current Options Chain. Who are some of Veracyte's key competitors? Some companies that are related to Veracyte include ELEKTA AB/ADR (EKTAY), InVitae (NVTA), Natera (NTRA), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Personalis (PSNL), Progenity (PROG), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Biocept (BIOC), Anpac Bio-Medical Science (ANPC) and Miragen Therapeutics (MGEN). View all competitors. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), CA (CA), Crispr Therapeutics (CRSP), AbbVie (ABBV), Advanced Micro Devices (AMD), Endologix (ELGX), BlackRock (BLK), InVitae (NVTA), Gilead Sciences (GILD) and Alibaba Group (BABA). Who are Veracyte's key executives? Veracyte's management team includes the following people: Ms. Bonnie H. Anderson, Co-Founder, Chairman & CEO (Age 61)Mr. Christopher M. Hall, Pres & COO (Age 50)Mr. Keith S. Kennedy CFA, CPA, CFO & Sec. (Age 49)Dr. Giulia C. Kennedy Ph.D., Chief Scientific & Medical Officer (Age 60)Mr. Ashish Kheterpal, Chief Information Officer What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." Who are Veracyte's major shareholders? Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (6.28%), Granite Investment Partners LLC (1.36%), Candriam Luxembourg S.C.A. (0.42%), Swiss National Bank (0.21%), Essex Investment Management Co. LLC (0.16%) and First Trust Advisors LP (0.12%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones, Giulia C Kennedy, Jesse I Treu, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy and Robert S Epstein. View institutional ownership trends for Veracyte. Which institutional investors are selling Veracyte stock? VCYT stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, Essex Investment Management Co. LLC, Falcon Point Capital LLC, SG Americas Securities LLC, Envestnet Asset Management Inc., First Trust Advisors LP, and Dupont Capital Management Corp. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, John Walter Hanna Jr, John Walter Hanna, Jr, Keith Kennedy, and Robert S Epstein. View insider buying and selling activity for Veracyte. Which institutional investors are buying Veracyte stock? VCYT stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Swiss National Bank, Exchange Traded Concepts LLC, Spearhead Capital Advisors LLC, ProShare Advisors LLC, Granite Investment Partners LLC, Zurcher Kantonalbank Zurich Cantonalbank , and M&T Bank Corp. View insider buying and selling activity for Veracyte. How do I buy shares of Veracyte? Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $31.38. How big of a company is Veracyte? Veracyte has a market capitalization of $1.59 billion and generates $120.37 million in revenue each year. The biotechnology company earns $-12,600,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veracyte employs 270 workers across the globe. What is Veracyte's official website? The official website for Veracyte is www.veracyte.com. How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
